What is the new oral pcsk 9 inhibitors
PCSK9 inhibitors have traditionally been injectable biologics (alirocumab, evolocumab). The first oral small-molecule PCSK9 inhibitor to reach late-stage trials is MK-0616 (from Merck), a macrocyclic peptide taken by mouth. There are also a few other candidates in the pipeline. Let me get you the latest clinical data.
Searching sources...
Searching PubMed
oral PCSK9 inhibitor small molecule
Searching the Web
oral PCSK9 inhibitor 2025 2026 MK-0616 clinical trial approval
Reading Article
PMID: 40167413
Reading Web Page
https://www.pharmacytimes.com/view/fda-approves-enlicitide-t…
This is excellent, very current data. Here is a full summary:
Oral PCSK9 Inhibitors - 2026 Update
What Makes Them Different from Injectable PCSK9 Inhibitors?
Traditional PCSK9 inhibitors (evolocumab/Repatha, alirocumab/Praluent) are monoclonal antibodies requiring subcutaneous injection every 2-4 weeks. Inclisiran (Leqvio) is a small-interfering RNA also given by injection. Oral delivery has been a long-sought goal to improve adherence and access.
1. Enlicitide Decanoate (MK-0616) - Brand name: Lipfendra - MERCK
FDA APPROVED: July 16, 2026 - This is breaking news (approved just yesterday).
- Mechanism: Macrocyclic peptide - a ring-shaped peptide structure that directly blocks PCSK9 from binding to the LDL receptor. Macrocyclization increases metabolic stability and oral bioavailability compared to standard linear peptides.
- Dose: 20 mg once daily tablet
- Indication: Adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH)
- Pivotal trial results (CORALreef program):
- CORALreef Lipids: 56% placebo-adjusted LDL-C reduction at 24 weeks
- CORALreef HeFH: 59% placebo-adjusted LDL-C reduction at 24 weeks
- Safety: Generally similar to placebo; in HeFH patients, diarrhea (7%) and dizziness (9%) were reported
- Note: A cardiovascular outcomes trial (MACE reduction) is ongoing - lipid lowering is proven, but MACE benefit is still under investigation
- Historic significance: First and only oral PCSK9 inhibitor ever approved by the FDA
The PURSUIT Phase II trial (JACC, 2025) also reported strong Phase 2 data for AZD0780 (see below), confirming the oral PCSK9 concept is now fully validated. [PMID: 40167413]
2. AZD0780 - ASTRAZENECA
- Mechanism: True small molecule oral PCSK9 inhibitor (not a peptide - a conventional small molecule)
- Status: Phase III clinical trials as of 2025 - not yet approved
- Phase II (PURSUIT trial, JACC 2025) - [PMID: 40167413]:
- Dose-dependent LDL-C reductions at 12 weeks:
- 1 mg: -35.3% vs placebo
- 3 mg: -37.9% vs placebo
- 10 mg: -45.2% vs placebo
- 30 mg: -50.7% vs placebo
- Safety comparable to placebo
- Dose-dependent LDL-C reductions at 12 weeks:
- Once-daily oral dosing on background statin therapy
- Phase III program is underway; an NDA has not yet been filed
Comparison Table
| Feature | Enlicitide (Lipfendra) | AZD0780 |
|---|---|---|
| Developer | Merck | AstraZeneca |
| Chemical class | Macrocyclic peptide | Small molecule |
| Regulatory status | FDA Approved (July 2026) | Phase III |
| Dosing | 20 mg once daily | Once daily (dose TBD) |
| LDL-C reduction | ~56-59% | ~35-51% (Phase II) |
| MACE data | Ongoing trial | Not yet |
Pipeline Context
Beyond these two, a review in Current Atherosclerosis Reports (Tokgözoğlu et al., [PMID: 40304930], April 2025) summarizes the broader question of whether oral PCSK9 inhibitors can replicate injectable antibody efficacy - the answer now appears to be yes for lipid lowering, with cardiovascular outcomes data pending.
Key takeaway: As of July 17, 2026, enlicitide decanoate (Lipfendra) - formerly known as MK-0616 - is the world's first FDA-approved oral PCSK9 inhibitor, approved literally yesterday. AstraZeneca's AZD0780 is the second major candidate, currently in Phase III with no approval yet.
This is a shared conversation. Sign in to Orris to start your own chat.